New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.
Start Your Search

New Drug Uses DNA Rather Than Tumor Type to Treat Cancer

The FDA just approved Loxo Oncology’s Vitrakvi drug that treats cancer in an unconventional way.

Cancer Cells in a Tray / Image: Suzanne Plunkett
Cancer Cells in a Tray / Image: Suzanne Plunkett

Most cancer treatments on the market are developed for specific types of cancer and seek approval for that one kind before organizing trials for other cancers. However, a recent Business Insider article discussed a new cancer treatment that focuses on the genetics of the patient. Loxo Oncology developed the drug, Vitrakvi, in partnership with Bayer.

Vitrakvi works for patients whose cancer tests positive for a type of mutation called a gene fusion in a gene called the neurotropic receptor tyrosine kinase, NTRK. For adults, the drug comes in 30-day supplies of 100-milligram capsules, and the cost is $393,600 annually. The liquid oral formulation for children and some adults will cost $121,000 annually. However, Bayer insists the out-of-pocket expense for the majority of patients will be $20 or less.

Test Your Smarts
Take Packaging World's sustainability quiz to prove your knowledge!
Take Quiz
Test Your Smarts
How to ensure your best conveying project yet
Read our latest Playbook to discover how to ensure efficient product handling, best practices for specifying conveyor and container handling equipment, and top tips for a successful pack line startup.
Download Now
How to ensure your best conveying project yet